patients and a group of controls. In all four patients studied serially an exaggerated TSH response to TRH developed soon after starting lithium and persisted throughout the period of observation. Basal TSH levels increased in two of the four patients within the first two weeks of treatment but no consistent trend was found in total thyroxine and total triiodothyronine levels. We suggest that the exaggerated TSH response to TRH is due mainly to the well established direct effects of lithium on the thyroid.
factors. That neither patient had discoloured teeth supports this theory. Discolouration of teeth occurs only if excess uroporphyrin is present when the dentine of the permanent teeth is being laid down and hence will not occur when the disease is of late onset. 4 There was no positive history of photosensitivity in other members of the family. A diagnostic concentration for erythrocyte uroporphyrin in latent heterozygotes for Gunther's disease must remain in doubt till more families are studied. In three family studies concentrations ranging from 48 to 1324 nmol/l (4-110 ,Lg/100 ml) of red cells have been found in presumed heterozygotes, whereas normal family members showed only a trace.'4 15 One of us (W.H.L.) has found erythrocyte uroporphyrin concentrations of 36 and 30 nmol/l (3-0 and 2-5 pg/ 100 ml) of red cells in the parents (presumed heterozygotes) of a very recently discovered second Australian patient and 51 nmol/l (4-2 jug/100 ml) in a sister. Thus, we provisionally accept a concentration of at least 30 nmol/l (2-5 4g/100 ml) of red cells as being consistent with the heterozygote state. On this criterion five of our patient's relatives would be latent heterozygotes, as were presumably his two deceased brothers. These results support a familial nature to this man's porphyria and thus future studies of the descendants of five uncles and six aunts of the patient would be worthwhile. ADDENDUM: Since this report was prepared the patient died with bronchopneumonia, and a poorly differentiated squamous cell carcinoma of the lung was found at necropsy. It is of interest that one brother also had a carcinoma of lung, and the other died with a myocardial infarct. Case 1.-A 54-year-old woman whose thyroid gland was just palpable. Thyroid function tests when lithium was stopped were: total T-4 37 nmol/l (normal 55-144 nmol/l), total T-3 0-79 nmol/l (normal 0-8-2-2 nmol/l), TSH 84 mU/l (normal 0-8 mU/l), and peak TSH increment after TRH 296 mU/l (normal 3-3-23 6 mU/l). One month later total T-4 was 59 nmol/l, total T-3 1 1 nmol/l, TSH 15 6 mU/l, and peak TSH increment after TRH 336 mU/l. After two months all values were within normal limits, the decrease in peak TSH response to TRH paralleling the fall in basal TSH levels.
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Case 2.-A 47-year-old woman with a small, diffuse goitre. Thyroid function tests when lithium was stopped were: total T-4 8 nmol/l, total T-3 0-5 nmol/l, TSH 138 mU/l, and peak TSH increment after TRH 62 mU/l. One month later total T-4 was 58 nmol/l, total T-3 1-2 nmol/l, TSH 73 mU/l, and peak TSH increment 112 mU/1. In contrast to case 1 the basal TSH remained raised for at least 10 T-4 levels. The exaggerated response to TRH in the remaining patients with normal basal TSH levels could have arisen in several ways. Vagenakis et al.,'4 have showed that acute reductions in total T-4 and T-3 within the respective normal ranges induced by iodide result in an increased TSH response to TRH. Possibly, therefore, lithium induces small decreases in circulating thyroid hormone levels which are too subtle to be readily detected by current methods. We found no significant difference in thyroid hormone levels between the euthyroid lithium-treated patients and a group of patients with affective disorders not receiving lithium matched for age and sex. Nor was there any consistent trend in thyroid hormone levels in the four patients studied serially. If, therefore, a reduction in thyroid hormone levels is the explanation of the exaggerated TSH response to TRH, then clearly the H.P.T. axis must be extremely sensitive to small changes in circulating thyroid hormone levels. Lithium may also have a central effect on the hypothalamus or pituitary or both or may alter the distribution space of TSH or its rate of degradation. Interestingly, lithium may reduce the rate of T-4 disappearance in hyperthyroid patients. 21 22 Despite the almost uniform exaggeration of TSH response to TRH which persists throughout treatment, only a few patients (two out of 21 (9%) in our study) progress to frank hypothyroidism. It has been suggested that hypothyroidism may occur only in patients with an underlying thyroid disorder. Thus a significantly higher incidence of antithyroglobulin antibodies has been observed in patients with raised basal TSH levels.7 Our observations, however, agree with the suggestion of Crowe et al.4 that hypothyroidism may develop in patients with no apparent evidence of underlying thyroiditis. Certainly, the exaggerated TSH response does not seem to be related to the presence of antibodies. At present there is no way of predicting which patients on lithium will develop hypothyroidism. Possibly those who show peak increments in TSH after TRH at the upper end of the normal range or a low T-3 response before starting lithium treatment may be most at risk of developing hypothyroidism, but further studies are required to test this hypothesis.
In one of our patients who developed hypothyroidism the exaggerated response to TRH was still present six months after lithium was stopped, and in the other patient TSH levels were raised one month after stopping lithium. This is considerably longer than the recovery of normal TSH levels in patients with primary hypothyroidism treated with the usual replacement doses of thyroid hormone.23 Utiger24 reported that in one patient with methimazole-induced hypothyroidism the plasma TSH levels fell to normal within one week of the recovery of endogenous thyroid hormone production. Whether the delayed return of basal TSH levels to normal in our two hypothyroid patients indicates a degree of thyroid failure or an unusually prolonged sensitivity to or slow clearance of lithium is unknown. Likewise, the possible relationship between the observed changes in H.P.T. function and the therapeutic effect of lithium remains to be established.
We do not believe that the presence of an exaggerated TSH response to TRH in the presence of normal basal TSH and thyroid hormone levels constitutes an indication for discontinuing lithium or prescribing T-4. We recommend, however, that thyroid function in patients on lithium is assessed periodically.
We are grateful to the National Institutes of Health, U.S.A., for the gift of the anti-human TSH serum, to the immunopathology laboratory of the Centre for Rheumatic Diseases, Glasgow, for measuring thyroid antibodies, to the department of biochemistry, Stobhill General Hospital for the lithium assays, and to the consultant psychiatrists who allowed us to study patients under their care.
Introduction
That medicaments can be absorbed through the skin has been known for a long time. While this route is usually of little significance percutaneous absorption of potent compounds can be important. The application of corticosteroid ointments and creams only permits an approximate dosage per unit area. An alternative approach is to use a range of steroid preparations of differing potency, so that an appropriate strength may be selected, depending on the diagnosis or severity of the disease.
The prolonged application of any potent corticosteroid may lead to atrophic skin changes and there is a risk of at least transient suppression ofhypothalamic-pituitary-adrenal (H.P.A.) function. Thus, a corticosteroid with greater topical antiinflammatory activity than hydrocortisone but lesser potential for inducing side effects than the more potent compounds is needed. We describe here studies performed with a new glucocorticoid-clobetasone butyrate-to investigate its antiinflammatory activity and effect on H.P.A. function in patients with skin diseases. The use of an animal model to assess atrophic potential is also described. fig. 1 . Clobetasone butyrate at 0-01% was similar to hydrocortisone 1%, at 0 025% it was rather more effective, and at 0 05°,, it was significantly more effective (P <0 05).
Though clobetasone butyrate 0 05% was not envisaged as being a primary treatment for psoriasis, which normally responds adequately only to the more potent steroids, we thought it appropriate to confirm the findings in eczema in patients with psoriasis. Differences in the relative activity of topical steroids are more readily shown in psoriasis,3 and hydrocortisone has little effect. Twelve patients with psoriasis were studied in a double-blind trial, usingclobetasonebutyrateO05% in a simple paraffinointment base underocclusive dressings. Ten patients responded better to the clobetasone butyrate and two to the hydrocortisone ointment. Though the new steroid was more effective than hydrocortisone, the psoriasis did not respond to it as well as would have been expected had the condition been treated with betamethasone valerate or clobetasol propionate.
The activity of clobetasone butyrate 0 05",, cream and ointment was further investigated in double-blind comparisons with fluocortolone
